^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) + Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P51.01 - Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
Published date:
08/18/2021
Excerpt:
In the INSIGHT study, 18 patients with METamp received tepotinib plus gefitinib...A total of 12/18 (67%) patients had a response; 4/6 in PIb with a duration of response (DOR) of 5.5, 5.6, 11.7, and 12.5 months, respectively, and 8/12 patients in PII with a median (m) DOR of 19.9 months (90% CI: 7.0, NE). In PII, mPFS was 16.6 months (8.3, NE) and mOS was 37.3 months (NE, NE); both greatly improved versus chemotherapy...
Trial ID:
